166 related articles for article (PubMed ID: 20412322)
1. BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study.
Windyga J; Rusen L; Gruppo R; O'Brien AC; Kelly P; Roth DA; Arkin S
Haemophilia; 2010 Sep; 16(5):731-9. PubMed ID: 20412322
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII.
Recht M; Nemes L; Matysiak M; Manco-Johnson M; Lusher J; Smith M; Mannucci P; Hay C; Abshire T; O'Brien A; Hayward B; Udata C; Roth DA; Arkin S
Haemophilia; 2009 Jul; 15(4):869-80. PubMed ID: 19473411
[TBL] [Abstract][Full Text] [Related]
3. Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience.
Stieltjes N; Altisent C; Auerswald G; Négrier C; Pouzol P; Reynaud J; Roussel-Robert V; Savidge GF; Villar A; Schulman S
Haemophilia; 2004 Sep; 10(5):452-8. PubMed ID: 15357770
[TBL] [Abstract][Full Text] [Related]
4. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Ghandehari H; Chapman M; Fritsch S; Wong WY; Pavlova BG; Abbuehl BE
Haemophilia; 2014 Sep; 20(5):651-8. PubMed ID: 24697870
[TBL] [Abstract][Full Text] [Related]
6. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
Smith MP; Giangrande P; Pollman H; Littlewood R; Kollmer C; Feingold J;
Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
[TBL] [Abstract][Full Text] [Related]
7. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.
Boadas A; Fernández-Palazzi F; De Bosch NB; Cedeño M; Ruiz-Sáez A
Haemophilia; 2011 May; 17(3):422-7. PubMed ID: 21118333
[TBL] [Abstract][Full Text] [Related]
8. Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa.
Takedani H; Kawahara H; Kajiwara M
Haemophilia; 2010 Mar; 16(2):290-5. PubMed ID: 19925628
[TBL] [Abstract][Full Text] [Related]
9. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.
Lusher JM; Lee CA; Kessler CM; Bedrosian CL;
Haemophilia; 2003 Jan; 9(1):38-49. PubMed ID: 12558777
[TBL] [Abstract][Full Text] [Related]
10. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.
Brand B; Gruppo R; Wynn TT; Griskevicius L; Lopez Fernandez MF; Chapman M; Dvorak T; Pavlova BG; Abbuehl BE
Haemophilia; 2016 Jul; 22(4):e251-8. PubMed ID: 27328112
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
[TBL] [Abstract][Full Text] [Related]
13. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.
Auerswald G; Bade A; Haubold K; Overberg D; Masurat S; Moorthi C
Haemophilia; 2013 May; 19(3):438-44. PubMed ID: 23279056
[TBL] [Abstract][Full Text] [Related]
14. SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies.
Négrier C; Lienhart A; Numerof R; Stephens D; Wong WY; Baghaei F; Yee TT
Haemophilia; 2013 May; 19(3):e143-50. PubMed ID: 23282031
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies.
Rusen L; Kavakli K; Korth-Bradley J; Huard F; Rendo P; Fuiman J; Baumann JA; Smith L; Alvey C; Rupon J
Haemophilia; 2018 Jul; 24(4):604-610. PubMed ID: 29582525
[TBL] [Abstract][Full Text] [Related]
16. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A.
Mahlangu JN; Ragni M; Gupta N; Rangarajan S; Klamroth R; Oldenburg J; Nogami K; Young G; Cristiano LM; Dong Y; Allen G; Pierce GF; Robinson B
Thromb Haemost; 2016 Jul; 116(1):1-8. PubMed ID: 26962852
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A.
Hyun SY; Park SY; Lee SY; Kook H; Paik SH; Jang IJ; Lee KS
Yonsei Med J; 2015 Jul; 56(4):935-43. PubMed ID: 26069114
[TBL] [Abstract][Full Text] [Related]
18. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients.
Négrier C; Shapiro A; Berntorp E; Pabinger I; Tarantino M; Retzios A; Schroth P; Ewenstein B
Thromb Haemost; 2008 Aug; 100(2):217-23. PubMed ID: 18690340
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
Klukowska A; Windyga J; Batorova A
Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A.
Xue F; Zhao X; Sun J; Zeng X; Yang F; Xu M; Yu Z; Gu W; Feng Y; Li W; Zheng C; Bi H; Xie L; Gai W; Yang R
Haemophilia; 2021 Sep; 27(5):814-822. PubMed ID: 34089210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
